TRIM31 and hepatocellular carcinoma: Using integrated investigation systems, including cellular models, animal models, and clinical liver cancer specimens, TRIM31 promoted HCC progression by inducing K48‐linked poly‐ubiquitous degradation of the tuberous sclerosis complex (TSC), the 1‐TSC2 complex, and the p53‐AMPK axis to mediate anoikis resistance.10, 55